iShares US Pharmaceuticals ETF
155 hedge funds and large institutions have $359M invested in iShares US Pharmaceuticals ETF in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 42 increasing their positions, 32 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
31% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 32
8% more funds holding
Funds holding: 143 → 155 (+12)
2.58% more ownership
Funds ownership: 56.66% → 59.25% (+2.6%)
4% less capital invested
Capital invested by funds: $374M → $359M (-$14.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$12.4M |
| 2 |
Morgan Stanley
New York
|
+$10.6M |
| 3 |
Two Sigma Investments
New York
|
+$4.64M |
| 4 |
PCA
Pallas Capital Advisors
Braintree,
Massachusetts
|
+$4.01M |
| 5 |
Goldman Sachs
New York
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RW
Rockport Wealth
Fairview Park,
Ohio
|
-$14.5M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$8.64M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3M |
| 4 |
SCA
Southern Capital Advisors
Jackson,
Tennessee
|
-$2.84M |
| 5 |
KDA
Kraft Davis & Associates
St. Louis,
Missouri
|
-$1.7M |
IHE Hedge Fund Activity: Q4 2024 in Review
155 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2024, worth a combined $359M — down 3.9% from $374M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IHE positions and 16 closed out — a net gain of 14 holders — while 42 added to existing stakes and 32 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $12.4M. The largest seller was Rockport Wealth, exiting entirely with an estimated $14.5M sold.
- 155 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2024, up from 143 in Q3 2024.
- Funds reported $359M of iShares US Pharmaceuticals ETF stock for Q4 2024, down 3.9% quarter-over-quarter.
- 30 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2024 and 16 closed out, a net change of +14 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2024 was JP Morgan Chase, an estimated $12.4M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2024 was Rockport Wealth, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2024.